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Background Acquired perforating dermatosis (APD) comprises an uncommon group of
skin disorders that develop in adulthood in association with systemic diseases. The aim of
this study was to characterize clinicopathologic features and treatment outcomes in a
series of patients diagnosed with APD.
Methods Retrospective study of all patients diagnosed with an APD over a 10-year period
(2009–2018) at a tertiary teaching hospital in Lisbon, Portugal.
Results Fifty-seven patients with APD were identified. Thirty-five patients presented
lesions in multiple anatomic areas (61.4%), and the lower limbs were the most common
location. Forty-six patients reported pruritus (80.7%), which was classified as severe in 21
of them (36.8%). An underlying systemic disease was identified in 53 patients (93.0%).
Diabetes mellitus (DM) and chronic kidney disease (CKD) were the most common
associated systemic diseases, but psychiatric disorders, malignancies, and chronic
infections were present in a significant number of patients. The combination of topical
steroids with antihistamines was the most prescribed initial treatment, but only 37.8% of
the patients had a complete response. Acitretin, systemic steroids, and phototherapy were
the treatments associated with the best outcome.
Conclusion Acquired perforating dermatosis can be associated with many systemic disorders
that have pruritus as a common factor. Chronic viral infections and an occult malignancy
should be sought, particularly in the absence of DM and CKD. Themanagement of APD is
challenging and is best achieved with the control of the underlying systemic diseases.
Introduction
Acquired perforating dermatosis (APD) comprises an uncom-
mon group of skin disorders characterized by transepidermal
elimination of dermal connective tissue components.1
Acquired perforating dermatosis usually develops in adult-
hood in association with diabetes mellitus (DM) and chronic kid-
ney disease (CKD), but many other systemic disorders have
been recently reported.2–6
Although there are a growing number of published case
reports of APD, few series evaluate clinicopathologic features
and management of patients with this disorder.
The aim of this study was to characterize a group of patients
with the diagnosis of APD, focusing on associated systemic dis-
eases and treatment outcomes.
Materials and Methods
A retrospective study was conducted on all patients
histopathologically diagnosed with an APD between January 1st,
2009, and December 31st, 2018, at Hospital de SantaMaria, a
tertiary teaching hospital in Lisbon, Portugal. Data were obtained
by reviewing dermatopathology registries and the clinical records.
A total of 57 patients were included in our study. The
information recorded for each patient included gender, age,
clinical features, distribution of skin lesions, clinical and
histopathological diagnosis, associated systemic diseases, and
treatment.
Treatment outcome was classified as complete response if
there were no residual lesions or symptoms, partial response
if there was an improvement but persistent lesions and/or
pruritus, and no response if there was no improvement.
Renal function was measured by calculating estimated
glomerular function rate (eGFR) using the abbreviated
Modification of Diet in Renal Disease (MDRD) equation:
GFR = 175 9 (serum creatinine [mg/dL])1.154 9 (age
[years])0.203 9 0.742 (if female) 9 1.21 (if African American).7
Data were analyzed using the IBM SPSS Statistics
(Statistical Package for the Social Sciences, version 24, SPSS
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Inc, Chicago, IL, USA). Categorical variables were presented as
frequencies and percentages, and continuous variables were
presented as means and standard deviations or medians and
interquartile ranges, for variables with skewed distribution.
Results
Demographical and clinical characteristics
Fifty-seven patients with APD were identified. Patient demo-
graphic and clinical characteristics are shown in Table 1.
Thirty-five patients presented lesions in multiple anatomic
areas (61.4%), and the lower limbs were the most common
location.
Forty-six patients reported pruritus (80.7%), which was classi-
fied as severe in 21 of them (36.8%). No patient reported pain.
Diagnosis of APD was clinically suspected in 23 patients
(40.4%). The differential diagnoses mostly considered were prur-
igo nodularis, pityriasis lichenoid, calciphylaxis, and folliculitis.
Associated systemic disorders
An underlying systemic disease was identified in 53 patients
(93.0%). Twenty-four of these patients had more than one sys-
temic disease (42.1%). Associated systemic disorders are sum-
marized in Table 2 and Fig. 1.
Twenty-seven patients had type 2 DM (47.4%), and one had
type 1 DM. Eighteen patients were taking only oral antidiabetic
drugs (31.6%), and 10 had insulin-treated DM (17.5%). The
mean glycated hemoglobin (HbA1C) was 8.0% (1.5), with a
range between 5.8 and 11.0%. Nine patients presented an
HbA1C higher than 8.0% (15.8%).
Six patients with CKD (10.5%) were on kidney replacement
therapy, five on hemodialysis (8.8%), and one on peritoneal
dialysis. One patient was a kidney transplant recipient. The
mean creatinine clearance was 28.9 mL/min/m2 (29.5), with a
range between 0 and 67 mL/min/m2. Diabetic nephropathy was
the most common etiology of CKD (n = 10; 17.5%).
The most frequent psychiatric diseases were depressive syn-
drome (n = 9; 15.8%) and anxiety disorder (n = 8; 14.0%). One
patient had delusional parasitosis.
Among the nine patients with the diagnosis of a malignancy,
four had a hematologic malignancy (two multiple myeloma, two
non-Hodgkin lymphoma), three had solid organ neoplasms
(lung, breast, and cervical cancer), and two had Kaposi sar-
coma.
Chronic infectious diseases were present in eight patients,
three of whom had human immunodeficiency virus (HIV) infec-
tion in acquired immunodeficiency syndrome (AIDS) stage
(Fig. 2), two had hepatitis C virus (HCV), and one hepatitis B
virus (HBV) infection. Two patients had chronic bacterial infec-
tions, of an orthopedic prothesis and a hepatic abscess.
A concomitant dermatological disorder was present in six
patients (10.5%). Psoriasis was the most frequent cutaneous
disease (n = 4; 7.0%), followed by atopic eczema and bullous
pemphigoid, each diagnosed in one patient.
Arterial hypertension and cardiovascular diseases were fre-
quent comorbidities, present in 30 (52.6%) and 23 (40.4%)
patients with APD, respectively. Chronic venous insufficiency,
peripheral arterial disease, ischemic heart disease, stroke, and
heart failure were the most commonly recorded cardiovascular
diseases.
Treatment and outcomes
The treatment modalities and outcomes are shown in Table 3.
The combination of topical steroids with antihistamines was the
most prescribed initial treatment. In some patients, these drugs
were combined with other treatments with a complete response:
Table 1 Patient demographic and clinical characteristics
Patient demographic and clinical
characteristics APD (n = 57)
Age at the diagnosis, mean (SD), years 61.3 (15.4) [range 37–96]
Male gender, No. (%) 29 (50.9)
Anatomic distribution, No. (%)
Lower limbs 40 (70.2)
Upper limbs 26 (45.6)
Trunk 25 (43.9)
Head and neck 4 (7.0)
Clinical features, No. (%)
Excoriated and hyperkeratotic papules 26 (45.6)
Keratotic plugged, umbilicated papules 18 (31.6)
Crusted ulcers 7 (12.3)
APD, acquired perforating dermatosis; SD, standard deviation.
Table 2 Underlying systemic disorders
Underlying systemic disorders No. (%)
DM 28 (49.1)
CKD 16 (28.1)
Psychiatric disorders 12 (21.1)
Malignancies 9 (15.8)
Infectious diseases 8 (14.0)
Hypothyroidism 5 (8.8)
Gastroenterological diseases (extrahepatic cholestasis,
celiac disease; ulcerative colitis, Wilson disease treated with
Penicillamine)
5 (8.8)
Rheumatological diseases (Sj€ogren syndrome, Still disease,
APS, CREST syndrome, psoriatic arthritis)
5 (8.8)
Neurological diseases (Alzheimer disease, normal pressure
hydrocephalus, epilepsy, amyloidotic familiar
polyneuropathy)
4 (7.0)
APS, antiphospholipid syndrome; CKD, chronic kidney disease;
CREST, calcinosis, Raynaud’s phenomenon, esophageal dysmotil-
ity, sclerodactyly, and telangiectasia; DM, diabetes mellitus.
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systemic steroids in five patients with disseminated APD, bile
duct dilatation in a patient with an iatrogenic stenosis, narrow-
band UVB (nbUVB) in a patient with concomitant eczema, topi-
cal calcipotriol in a patient with psoriasis, and switch of
immunosuppression from tacrolimus to sirolimus in a kidney
transplant recipient. Intralesional steroids and doxycycline were
used as first-line treatment in two patients, with a partial and no
response, respectively.
After an incomplete response to initial treatment, second-line
drugs included acitretin, systemic steroids, intralesional steroids,
doxycycline, allopurinol, and psoralen plus UVA (PUVA) ther-
apy. Acitretin, systemic steroids, and PUVA therapy were the
treatments with best outcome.
After treatment, 31 patients had complete resolution of skin
lesions (54.4%), 13 presented partial improvement (22.8%), and
one presented no response. Five patients died within 6 months
after the diagnosis of APD (8.8%).
Patients presented a faster and more complete response for
the resolution of the skin lesions than for the relief of pruritus.
Discussion
Since the first description of a case of APD in a diabetic woman
in 1916 by Kyrle, four distinct entities have been identified and
distinguished by the composition of the extruded material




Figure 1 (a) Annular papular keratotic lesions on the posterior neck
of a woman diagnosed with Wilson’s disease for which she was
taking D-penicillamine for the last 12 years. (b, c) Histological
examination showing transepithelial elimination of degenerated
elastic fibers with a “lumpy-bumpy” pattern [(Periodic acid-Schiff,
9100); (Verhoeff-van Gieson, 9100), respectively]
(a)
(b)
Figure 2 (a) Keratotic plugged, umbilicated papules on the trunk
and upper limbs of a man with HIV infection in the stage of AIDS;
(b) Histological examination showing cup-shaped invagination of the
epidermis, filled with basophilic degenerated collagen fibers, keratin,
and crust (H&E, 9100)
ª 2019 The International Society of Dermatology International Journal of Dermatology 2020, 59, 445–450
Garrido et al. Acquired perforating dermatosis Report 447
perforans serpiginosa, Kyrle disease, and perforating folliculitis.1
However, overlapping features in pathologic examination in the
same lesion can coexist, and some patients seem to present
more than one subtype, making this classification unprecise.6,8,9
The term APD has been used to describe perforating dermato-
sis arising in adult patients with systemic diseases.6
The underlying systemic diseases most commonly reported
are DM and CKD, but an increasing number of disorders have
been associated with APD.2–6 In this study, DM was the most
common, and most patients were taking oral antidiabetic drugs.
Similarly, previous series found a higher proportion of cases in
non-insulin-dependent patients.3,9,10 In contrast, Morton et al.
reported a higher number of insulin-dependent patients and
suggested that these individuals were more likely to have sus-
tained hyperglycemia and a longer duration of DM.11 The Amer-
ican Diabetes Association defines an HbA1C lower than 8.0%
as the target for glycemic control in high-risk patients, such as
those with CKD.12 In the present study, mean HbA1C was
8.0%, and 32.1% of diabetic patients had a HbA1C higher than
the defined target, emphasizing the possible role of poor glyce-
mic control in the pathogenesis of APD.
Chronic kidney disease was the second most reported under-
lying systemic disease. The main cause of CKD was diabetic
nephropathy, as in previous studies.3,6,11,13 Contrasting with
other series, only 37.5% of the patients with CKD were receiv-
ing kidney replacement therapy.2,6,13 Although APD is scarcely
reported in association with solid organ transplant, George et al.
reported a prevalence of 2.7% in a series of kidney transplant
recipients.14 We identified a case in a kidney transplant recipi-
ent without DM who was successfully treated with the combina-
tion of topical steroids, antihistamines, and the switch of
immunosuppression from tacrolimus to sirolimus. This outcome
contrasts with another report of APD that presented in a liver
transplant recipient after starting therapy with sirolimus.15 The
pathophysiology behind immunosuppressive drugs and the
development of APD has yet to be established.
Psychiatric disorders not only can elicit pruritus and promote
its persistence, but also chronic pruritus can decrease the qual-
ity of life and induce depressive and anxiety disorders.16 How-
ever, there are few reports of psychiatric diseases in patients
diagnosed with APD.4,17 In the present series, psychiatric disor-
ders affected 22 patients (21.1%), and in five of them, there
was no other underlying systemic disease.
The association of APD with malignancy has been reported
both in patients with lymphoproliferative disorders, in particular
Hodgkin disease, and in patients with solid organ neoplasms,
such as prostate, hepatocellular, and breast carcinoma.18–25
Remarkably, APD was previously reported as the first presenta-
tion of an occult malignancy, and some authors suggest that
this disorder might represent a paraneoplastic condition.22,24 In
this series, an underlying malignancy was present in 15.8% of
the patients. An occult neoplasm should be actively sought in
the presence of suspicious symptoms, particularly in the
absence of other underlying systemic diseases.
Chronic viral infections have also been associated with APD,
namely HIV infection and chronic viral hepatitis.5,6,13,26–28 More-
over, protease inhibitors, including telaprevir and indinavir, have
been implicated in its development as these drugs can elicit
pruritus.26,29 Interestingly, in the present study, all patients with
HIV infection presented in the setting of AIDS. Only one of
these three patients was taking a protease inhibitor, and no
other underlying systemic disease was identified, suggesting
that the infection itself can induce the development of APD.
Although hypertension and cardiovascular diseases were fre-
quent comorbidities in this study, we hypothesize that these dis-
orders were not the dominant factor implicated in the
development of APD, given its high prevalence on overall popu-
lation and the fact that almost all of the patients presented other
underlying systemic diseases, in particular DM and CKD. How-
ever, Garcıa-Malinis et al. proposed that vasculopathy underly-
ing chronic venous insufficiency and hypertension might be








Topical steroids and antihistamines
(n = 37)
14 (37.8%) 13 (35.1%) 6 (16.2%) 4
(10.8%)
Systemic steroids (n = 7) 6 (85.7%) – – 1
(14.3%)
Intralesional steroids (n = 5) 1 (20.0%) 4 (80.0%) – –
Acitretin (n = 4) 3 (75.0%) 1 (25.0%) – –
Doxycycline (n = 2) – 1 (50.0%) 1 (50.0%) –
Allopurinol (n = 1) – – 1 (100.0%) –
PUVA therapy (n = 1) 1 (100.0%) – – –
nbUVB (n = 1) 1 (100.0%) – – –
Topical calcipotriol (n = 1) 1 (100.0%) – – –
nbUVB, narrowband UVB; PUVA, Psoralen UVA.
Table 3 Treatment and outcomes
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The management of APD is challenging, and the evidence-
based support for treatment comes from small case series and
individual case reports.30 Treatment of underlying systemic dis-
eases should always be considered and, sometimes, complete
resolution of the dermatosis might be achieved. The association
of topical steroids with oral antihistamines is usually the first
modality of treatment. In contrast with previous series, only
37.8% of the patients had a complete response, emphasizing
the need for other treatment options.2,3 Successful outcomes
with tetracyclines, allopurinol, phototherapy, systemic retinoids,
and systemic steroids have been reported.2–4,30–32 In this ser-
ies, few patients were treated with doxycycline and allopurinol,
and both drugs were not an effective treatment alternative. Aci-
tretin, systemic steroids, and phototherapy were the treatments
associated with the best outcome and should be considered in
the management of patients with disseminated lesions and sev-
ere pruritus, as well as in those who have a poor response to
topical therapies.
The main limitations of this study rise from the fact that it has
a retrospective design, with data obtained through the analysis
of histopathology registries and medical records from a single
center. Nevertheless, to the best of our knowledge, this is the
largest series of APD.
Conclusion
Acquired perforating dermatosis is an uncommon group of skin
disorders associated with a wide spectrum of systemic diseases
that have pruritus as a common factor. Chronic viral infections
and an occult malignancy should be sought, particularly in the
absence of DM and CKD. The management of APD is challeng-
ing and is best achieved with control of the underlying systemic
disorders.
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17 Tampa M, Sârbu MI, Matei C, et al. Kyrle’s disease in a patient
with delusions of parasitosis. Rom J Intern Med 2016; 54: 66–69.
18 Rivera-Rodrıguez A, Prieto-Torres L, Felipo-Berlanga F, et al.
Acquired reactive perforating collagenosis associated with
Hodgkin disease. Clin Exp Dermatol 2017; 42: 934–936.
19 Eigentler TK,MetzlerG, Brossart P, et al. Acquired perforating
collagenosis inHodgkin’s disease. JAmAcadDermatol2005; 52: 922.
20 Quinlan C, Boggs J, Finan M, et al. A case of paraneoplastic
elastosis perforans serpiginosa associated with ovarian
malignancy. Int J Dermatol 2018; 57: 470–472.
21 Singh EN, Kumar S, Agarwal US, et al. Acquired reactive
perforating collagenosis associated with mediastinal synovial
sarcoma. Clin Exp Dermatol 2019; 44: 325–327.
22 Yazdi S, SaadatP, YoungS, et al. Acquired reactive perforating
collagenosis associated with papillary thyroid carcinoma: a
paraneoplastic phenomenon?Clin ExpDermatol2010; 35: 152–155.
23 Kim RH, Kwa M, Adams S, et al. Giant acquired reactive
perforating collagenosis in a patient with diabetes mellitus and
metastatic breast carcinoma. JAAD Case Rep 2016; 2: 22–24.
24 Kurban M, Uthman I, Kibbi AG, et al. Acquired perforating
dermatosis heralding metastatic renal cell carcinoma to the
liver. Int J Dermatol 2008; 47: 1038–1040.
25 Lee YS, Vijayasingam S, Tan YO, et al. Acquired perforating
dermatosis associated with recurrent hepatocellular carcinoma.
Int J Dermatol 1996; 35: 743–745.
26 Pernet C, PageauxGP,Guillot B, et al. Telaprevir-inducedacquired
perforating dermatosis. JAMADermatol 2014; 150: 1371–1372.
ª 2019 The International Society of Dermatology International Journal of Dermatology 2020, 59, 445–450
Garrido et al. Acquired perforating dermatosis Report 449
27 Rubio FA, Herranz P, Robayna G, et al. Perforating folliculitis:
report of a case in an HIV-infected man. J Am Acad Dermatol
1999; 40(2 Pt 2): 300–302.
28 Nogueira Farias GM, Pinto JR, Melo JC, et al. Kyrle’s disease
associated with HIV infection, diabetes, and chronic kidney
disease. Indian J Pathol Microbiol 2018; 61: 414–417.
29 Calista D, Morri M. Acquired reactive perforating collagenosis
induced by indinavir in 2 patients with HIV disease. Eur J
Dermatol 2008; 18: 84–85.
30 Lukacs J, Schliemann S, Elsner P. Treatment of acquired
reactive perforating dermatosis – a systematic review. J Dtsch
Dermatol Ges 2018; 16: 825–842.
31 Karpouzis A, Giatromanolaki A, Sivridis E, et al. Acquired
reactive perforating collagenosis: current status. J Dermatol
2010; 37: 585–592.
32 Hoque SR, Ameen M, Holden CA. Acquired reactive perforating
collagenosis: four patients with a giant variant treated with
allopurinol. Br J Dermatol 2006; 154: 759–762.
International Journal of Dermatology 2020, 59, 445–450 ª 2019 The International Society of Dermatology
Report Acquired perforating dermatosis Garrido et al.450
